ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development,
manufacture and sale of innovative medical devices used in infusion
therapy and critical care applications, today announced financial
results for the quarter ended March 31, 2017.
First Quarter 2017 Results
First quarter 2017 revenue was $247.7 million, compared to $89.9
million in the same period last year. GAAP gross profit for the
first quarter of 2017 was $88.9 million, as compared to $49.2
million in the same period last year. GAAP gross margin for
the first quarter of 2017 was 36%, as compared to 55% in the same
period last year. GAAP net income for the first quarter of
2017 was $55.9 million, or $2.86 per diluted share, as compared to
GAAP net income of $18.2 million, or $1.08 per diluted share, for
the first quarter of 2016, which were both adjusted from the
previously announced adoption of FASB ASU 2016-09,
Improvements to Employee Share-based Payment Accounting, effective
January 1, 2016.
Adjusted net sales for the first quarter of 2017 was $248.1
million. Adjusted gross profit for the first quarter of 2017 was
$111.0 million. Adjusted gross margin for the first quarter
of 2017 was 45%. Adjusted diluted earnings per share for the
first quarter of 2017 were $1.68 as compared to $1.26 for the first
quarter of 2016. Also, adjusted EBITDA was $50.1 million for the
first quarter of 2017 as compared to $32.7 million for the first
quarter of 2016.
Adjusted net sales, adjusted gross profit, adjusted gross
margin, adjusted diluted earnings per share and adjusted EBITDA are
measures calculated and presented on the basis of methodologies
other than in accordance with GAAP. Please refer to the Use
of Non-GAAP Financial Information following the financial
statements herein for further discussion and reconciliations of
these measures to GAAP measures.
Vivek Jain, ICU Medical's Chief Executive Officer, said,
"Revenues were in-line with our expectations and our adjusted
EBITDA and adjusted earnings per share were slightly ahead of our
expectations due to minor discrete accounting and tax benefits.
Integration activities are progressing as planned.”
Revenues by market segment for the three months ended
March 31, 2017 and 2016 were as follows (in millions):
The following market segment results for the first quarter of
2017 includes our legacy business and our Hospira Infusion Systems
business from the point of closing of the acquisition, which was
February 3, 2017, through the end of the first quarter of 2017.
|
|
Three months endedMarch
31, |
|
|
|
|
Market Segment |
|
2017 |
|
2016 |
|
$ Change |
|
%Change |
Infusion Systems |
|
$ |
46.7 |
|
|
$ |
— |
|
|
$ |
46.7 |
|
|
100.0 |
% |
Infusion
Consumables |
|
75.7 |
|
|
76.7 |
|
|
(1.0 |
) |
|
(1.3 |
)% |
IV Solutions |
|
97.4 |
|
|
— |
|
|
97.4 |
|
|
100.0 |
% |
Critical Care |
|
12.4 |
|
|
13.0 |
|
|
(0.6 |
) |
|
(4.6 |
)% |
Other |
|
15.5 |
|
|
0.2 |
|
|
15.3 |
|
|
7,650.0 |
% |
|
|
$ |
247.7 |
|
|
$ |
89.9 |
|
|
$ |
157.8 |
|
|
175.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company ended the first quarter of 2017 with a strong
balance sheet. As of March 31, 2017, cash and cash equivalents
totaled $201.9 million, working capital was $725.9 million and
long-term debt obligations of $75 million.
Conference Call
The Company will host a conference call to discuss first quarter
2017 financial results today at 4:30 p.m. EDT (1:30 p.m.
PDT). The call can be accessed at (800) 936-9761,
international (408) 774-4587, conference ID 13657052. The
conference call will be simultaneously available by webcast, which
can be accessed by going to the Company's website at
www.icumed.com, clicking on the Investors tab, clicking on the
Webcast icon and following the prompts. The webcast will also be
available by replay.
About ICU Medical, Inc.
ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells
innovative medical devices used in vascular therapy, and critical
care applications. ICU Medical's product portfolio includes IV
smart pumps, sets, connectors, closed transfer devices for
hazardous drugs, cardiac monitoring systems, along with pain
management and safety software technology designed to help meet
clinical, safety and workflow goals. ICU Medical is headquartered
in San Clemente, California. More information about ICU Medical,
Inc. can be found at www.icumed.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements contain words such as ''will,''
''expect,'' ''believe,'' ''could,'' ''would,'' ''estimate,''
''continue,'' ''build,'' ''expand'' or the negative thereof or
comparable terminology, and may include (without limitation)
information regarding the Company's expectations, goals or
intentions regarding the future, and our recently completed
acquisition of the Hospira infusion systems business. These
forward-looking statements are based on management's current
expectations, estimates, forecasts and projections about the
Company and assumptions management believes are reasonable, all of
which are subject to risks and uncertainties that could cause
actual results and events to differ materially from those stated in
the forward-looking statements. These risks and uncertainties
include, but are not limited to, decreased demand for the Company's
products, decreased free cash flow, the inability to recapture
conversion delays or part/resource shortages on anticipated timing,
or at all, changes in product mix, increased competition from
competitors, lack of continued growth or improving efficiencies,
unexpected changes in the Company's arrangements with its largest
customers and the Company’s ability to meet expectations regarding
the integration of the Hospira infusion systems business. Future
results are subject to risks and uncertainties, including the risk
factors, and other risks and uncertainties, described in the
Company's filings with the Securities and Exchange Commission,
which include those in the Annual Report on Form 10-K for the year
ended December 31, 2016 and our subsequent filings. Forward-looking
statements contained in this press release are made only as of the
date hereof, and the Company undertakes no obligation to update or
revise the forward-looking statements, whether as a result of new
information, future events or otherwise.
|
ICU MEDICAL, INC. AND
SUBSIDIARIES |
CONDENSED CONSOLIDATED BALANCE
SHEETS |
(In thousands) |
|
|
March 31,2017 |
|
December 31, 2016 |
|
(unaudited) |
|
(1) |
ASSETS |
|
|
|
CURRENT ASSETS: |
|
|
|
Cash and
cash equivalents |
$ |
201,862 |
|
|
$ |
445,082 |
|
Accounts
receivable, net |
137,699 |
|
|
56,161 |
|
Inventories |
445,684 |
|
|
49,264 |
|
Prepaid
income taxes |
12,196 |
|
|
11,235 |
|
Prepaid
expenses and other current assets |
86,594 |
|
|
7,355 |
|
Assets
held for sale |
2,508 |
|
|
— |
|
TOTAL
CURRENT ASSETS |
886,543 |
|
|
569,097 |
|
|
|
|
|
PROPERTY AND EQUIPMENT,
net |
377,756 |
|
|
85,696 |
|
OTHER ASSETS |
31,823 |
|
|
— |
|
GOODWILL |
6,583 |
|
|
5,577 |
|
INTANGIBLE ASSETS,
net |
159,135 |
|
|
22,383 |
|
DEFERRED INCOME
TAXES |
11,196 |
|
|
21,935 |
|
TOTAL ASSETS |
$ |
1,473,036 |
|
|
$ |
704,688 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
CURRENT
LIABILITIES: |
|
|
|
Accounts
payable |
$ |
37,427 |
|
|
$ |
14,641 |
|
Accrued
liabilities |
121,638 |
|
|
25,896 |
|
Income
tax liability |
1,614 |
|
|
— |
|
TOTAL
CURRENT LIABILITIES |
160,679 |
|
|
40,537 |
|
|
|
|
|
EARN-OUT LIABILITY |
19,000 |
|
|
— |
|
LONG-TERM
OBLIGATIONS |
75,000 |
|
|
— |
|
OTHER LONG-TERM
LIABILITIES |
68,832 |
|
|
1,107 |
|
DEFERRED INCOME
TAXES |
6,214 |
|
|
1,370 |
|
INCOME TAX
LIABILITY |
1,519 |
|
|
1,519 |
|
COMMITMENTS AND
CONTINGENCIES |
— |
|
|
— |
|
STOCKHOLDERS’
EQUITY: |
|
|
|
Convertible preferred stock |
— |
|
|
— |
|
Common
stock |
1,980 |
|
|
1,633 |
|
Additional paid-in capital |
586,212 |
|
|
162,828 |
|
Treasury
stock |
— |
|
|
(14 |
) |
Retained
earnings |
572,843 |
|
|
516,980 |
|
Accumulated other comprehensive loss |
(19,243 |
) |
|
(21,272 |
) |
TOTAL
STOCKHOLDERS' EQUITY |
1,141,792 |
|
|
660,155 |
|
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY |
$ |
1,473,036 |
|
|
$ |
704,688 |
|
|
|
|
|
|
|
|
|
______________________________________________________(1) December 31,
2016 balances were derived from audited consolidated financial
statements.
ICU MEDICAL, INC. AND
SUBSIDIARIES |
CONDENSED CONSOLIDATED STATEMENTS OF
INCOME (Unaudited) |
(In thousands, except per share data) |
|
|
Three months endedMarch
31, |
|
2017 |
|
2016 |
REVENUES: |
|
|
|
Net
sales |
$ |
231,788 |
|
|
$ |
89,849 |
|
Other |
15,951 |
|
|
6 |
|
TOTAL REVENUE |
247,739 |
|
|
89,855 |
|
COST OF GOODS SOLD |
158,794 |
|
|
40,622 |
|
GROSS
PROFIT |
88,945 |
|
|
49,233 |
|
OPERATING
EXPENSES: |
|
|
|
Selling,
general and administrative |
64,886 |
|
|
21,975 |
|
Research
and development |
11,641 |
|
|
3,313 |
|
Restructuring and strategic transaction |
29,401 |
|
|
— |
|
TOTAL OPERATING
EXPENSES |
105,928 |
|
|
25,288 |
|
INCOME FROM
OPERATIONS |
(16,983 |
) |
|
23,945 |
|
BARGAIN PURCHASE
GAIN |
63,237 |
|
|
— |
|
OTHER (EXPENSE) INCOME,
net |
(406 |
) |
|
147 |
|
INCOME BEFORE INCOME
TAXES |
45,848 |
|
|
24,092 |
|
BENEFIT (PROVISION) FOR
INCOME TAXES |
10,015 |
|
|
(5,932 |
) |
NET INCOME |
$ |
55,863 |
|
|
$ |
18,160 |
|
NET INCOME PER
SHARE |
|
|
|
Basic |
$ |
3.03 |
|
|
$ |
1.13 |
|
Diluted |
$ |
2.86 |
|
|
$ |
1.08 |
|
WEIGHTED AVERAGE NUMBER
OF SHARES |
|
|
|
Basic |
18,439 |
|
|
16,042 |
|
Diluted |
19,549 |
|
|
16,870 |
|
ICU MEDICAL, INC. AND
SUBSIDIARIES |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited) |
(In thousands) |
|
|
|
Three months endedMarch
31, |
|
2017 |
|
2016 |
CASH FLOWS FROM
OPERATING ACTIVITIES: |
|
|
|
Net income |
$ |
55,863 |
|
|
$ |
18,160 |
|
Adjustments to
reconcile net income to net cash provided by operating
activities: |
|
|
|
Depreciation and amortization |
11,594 |
|
|
4,801 |
|
Provision
for doubtful accounts |
13 |
|
|
— |
|
Provision
for warranty and returns |
1,286 |
|
|
39 |
|
Stock
compensation |
4,006 |
|
|
3,808 |
|
Loss
(gain) on disposal of property and equipment |
18 |
|
|
(1 |
) |
Bargain
purchase gain |
(63,237 |
) |
|
— |
|
Bond
premium amortization |
— |
|
|
528 |
|
Changes in operating
assets and liabilities: |
|
|
|
Accounts
receivable |
(82,266 |
) |
|
2,552 |
|
Inventories |
22,233 |
|
|
(4,866 |
) |
Prepaid
expenses and other assets |
(66,573 |
) |
|
(3,474 |
) |
Accounts
payable |
11,456 |
|
|
(1,383 |
) |
Accrued
liabilities |
39,907 |
|
|
(8,014 |
) |
Income
taxes, including excess tax benefits and deferred income taxes |
(10,909 |
) |
|
5,145 |
|
Net cash (used in)
provided by operating activities |
(76,609 |
) |
|
17,295 |
|
CASH FLOWS FROM
INVESTING ACTIVITIES: |
|
|
|
Purchases
of property and equipment |
(16,396 |
) |
|
(3,963 |
) |
Proceeds
from sale of assets |
— |
|
|
1 |
|
Business
acquisitions, net of cash acquired |
(157,097 |
) |
|
— |
|
Intangible asset additions |
(410 |
) |
|
(219 |
) |
Purchases
of investment securities |
— |
|
|
(7,061 |
) |
Proceeds
from sale of investment securities |
— |
|
|
11,802 |
|
Net cash (used in)
provided by investing activities |
(173,903 |
) |
|
560 |
|
CASH FLOWS FROM
FINANCING ACTIVITIES: |
|
|
|
Proceeds
from exercise of stock options |
8,992 |
|
|
5,421 |
|
Proceeds
from employee stock purchase plan |
1,326 |
|
|
1,197 |
|
Purchase
of treasury stock |
(3,718 |
) |
|
(16,897 |
) |
Net cash provided by
(used in) financing activities |
6,600 |
|
|
(10,279 |
) |
Effect of exchange rate
changes on cash |
692 |
|
|
3,630 |
|
NET (DECREASE) INCREASE
IN CASH AND CASH EQUIVALENTS |
(243,220 |
) |
|
11,206 |
|
CASH AND CASH
EQUIVALENTS, beginning of period |
445,082 |
|
|
336,164 |
|
CASH AND CASH
EQUIVALENTS, end of period |
$ |
201,862 |
|
|
$ |
347,370 |
|
|
|
|
|
|
|
|
|
Use of Non-GAAP Financial Information
This press release contains financial measures that are not
calculated in accordance with U.S. generally accepted accounting
principles ("GAAP"). The non-GAAP financial measures should
be considered supplemental to, and not as a substitute for, or
superior to, financial measures calculated in accordance with
GAAP. There are material limitations in using these non-GAAP
financial measures because they are not prepared in accordance with
GAAP and may not be comparable to similarly titled non-GAAP
financial measures used by other companies, including peer
companies. Our management believes that the non-GAAP data
provides useful supplemental information to management and
investors regarding our performance and facilitates a more
meaningful comparison of results of operations between current and
prior periods. We use non-GAAP financial measures in addition
to and in conjunction with GAAP financial measures to analyze and
assess the overall performance of our business, in making
financial, operating and planning decisions, and in determining
executive incentive compensation. The non-GAAP financial
measures included in this press release are adjusted net sales,
adjusted gross profit, adjusted gross profit margin, adjusted
EBITDA and adjusted diluted earnings per share ("Adjusted Diluted
EPS").
Adjusted net sales includes/excludes the following items from
net sales:
Excludes contract manufacturing revenue: We manufacture
certain products for Pfizer at cost in accordance with a
manufacturing services agreement. We do not include the
contract manufacturing revenue in our adjusted net sales as the
revenue under this agreement was negotiated contemporaneously with
our acquisition of Hospira from Pfizer and is not indicative of a
normal market transaction.
Includes ICU intercompany sales to Hospira: We include
intercompany sales to Hospira for inventory that we previously sold
to Hospira, which remained on the opening balance sheet of Hospira
after its acquisition by ICU.
Adjusted gross profit excludes the following from gross
profit:
Adjustment to reverse the cost recognition related to the
purchase accounting write-up of inventory to fair market value: The
inventory step-up represents the expense recognition of fair value
adjustments in excess of the historical cost basis of inventory
obtained through acquisition, these charges are outside of our
normal operations and are excluded.
Adjusted gross profit margin is calculated using the adjusted
gross profit as a percentage of the adjusted net sales as
determined above.
Adjusted EBITDA excludes the following items from net
income:
Interest, net: We exclude interest in deriving adjusted
EBITDA as interest can vary significantly among companies depending
on a company's level of income generating instruments and/or level
of debt.
Intangible asset amortization expense: We do not acquire
businesses or capitalize certain patent costs on a predictable
cycle. The amount of purchase price allocated to intangible
assets and the term of amortization can vary significantly and are
unique to each acquisition. Capitalized patent costs can vary
significantly based on our current level of development
activities. We believe that excluding amortization of
intangible assets provides the users of our financial statements
with a consistent basis for comparison across accounting
periods.
Depreciation expense: We exclude depreciation expense in
deriving adjusted EBITDA because companies utilize productive
assets of different ages and the depreciable lives can vary
significantly resulting in considerable variability in
depreciation expense among companies.
Stock compensation expense: Stock-based compensation is
generally fixed at the time the stock-based instrument is granted
and amortized over a period of several years. The value of
stock options is determined using a complex formula that
incorporates factors, such as market volatility, that are beyond
our control. The value of our restricted stock awards is
determined using the grant date stock price, which may not be
indicative of our operational performance over the expense
period. Additionally, in order to establish the fair value of
performance-based stock awards, which are currently an element of
our ongoing stock-based compensation, we are required to apply
judgment to estimate the probability of the extent to which
performance objectives will be achieved. Based on the above
factors, we believe it is useful to exclude stock-based
compensation in order to better understand our operating
performance.
Restructuring and strategic transaction: We incur
restructuring and strategic transaction charges that result from
events, which arise from unforeseen circumstances and/or often
occur outside of the ordinary course of our ongoing business.
Although these events are reflected in our GAAP financial
statements, these unique transactions may limit the comparability
of our ongoing operations with prior and future periods.
Bargain purchase gain: We may incur a bargain purchase
gain on certain acquisitions if the fair market value of the
identifiable assets acquired and liabilities assumed, net of
deferred taxes exceeds the total consideration paid. We
exclude such gains as they are related to acquisitions and have no
direct correlation to the operation of our ongoing business.
Adjusted Diluted EPS excludes from diluted EPS, net of
tax, interest, net, intangible asset amortization expense, stock
compensation expense, restructuring and strategic transaction, and
bargain purchase gain, which was tax free. We apply our GAAP
consolidated effective tax rate to our non-GAAP financial measures,
other than when the underlying item has a materially different tax
treatment.
From time to time in the future, there may be other items that
we may exclude if we believe that doing so is consistent with the
goal of providing useful information to investors and
management.
The following tables reconcile our GAAP and non-GAAP financial
measures:
ICU MEDICAL, INC. AND
SUBSIDIARIES |
Reconciliation of GAAP to Non-GAAP
Financial Measures (Unaudited) |
(In thousands) |
|
|
Adjusted net sales |
|
Three months endedMarch 31,
2017 |
|
Infusion Systems |
|
Infusion Consumables |
|
IVSolutions |
|
CriticalCare |
|
Other |
|
Total |
GAAP net sales |
$ |
46,670 |
|
|
$ |
75,712 |
|
|
$ |
97,370 |
|
|
$ |
12,397 |
|
|
$ |
15,590 |
|
|
$ |
247,739 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP
adjustments: |
|
|
|
|
|
|
|
|
|
|
|
Contract
manufacturing |
— |
|
|
— |
|
|
(14,656 |
) |
|
— |
|
|
|
|
(14,656 |
) |
ICU
intercompany sales to Hospira |
— |
|
|
14,968 |
|
|
— |
|
|
— |
|
|
|
|
14,968 |
|
Non-GAAP
net sales |
$ |
46,670 |
|
|
$ |
90,680 |
|
|
$ |
82,714 |
|
|
$ |
12,397 |
|
|
$ |
15,590 |
|
|
$ |
248,051 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted net sales |
|
Three months endedMarch 31,
2016 |
|
Infusion Systems |
|
Infusion Consumables |
|
IVSolutions |
|
CriticalCare |
|
Other |
|
Total |
GAAP net sales |
$ |
— |
|
|
$ |
76,641 |
|
|
$ |
— |
|
|
$ |
13,016 |
|
|
$ |
198 |
|
|
$ |
89,855 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP
adjustments: |
|
|
|
|
|
|
|
|
|
|
|
Contract
manufacturing |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
ICU
intercompany sales to Hospira |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Non-GAAP
net sales |
$ |
— |
|
|
$ |
76,641 |
|
|
$ |
— |
|
|
$ |
13,016 |
|
|
$ |
198 |
|
|
$ |
89,855 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted gross profit |
|
|
|
|
|
|
|
|
|
Three months endedMarch
31, |
|
|
|
|
|
|
|
2017 |
|
2016 |
|
|
|
|
|
|
|
|
GAAP gross profit |
$ |
88,945 |
|
|
$ |
49,233 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP
adjustments: |
|
|
|
|
|
|
|
|
|
|
|
Adjustment to reverse the cost recognition related to the purchase
accounting write-up of inventory to fair market value |
22,053 |
|
|
— |
|
|
|
|
|
|
|
|
|
Non-GAAP
gross profit |
$ |
110,998 |
|
|
$ |
49,233 |
|
|
|
|
|
|
|
|
|
GAAP
gross profit % GAAP net sales |
36 |
% |
|
55 |
% |
|
|
|
|
|
|
|
|
Non-GAAP
gross profit % Non-GAAP net sales |
45 |
% |
|
55 |
% |
|
|
|
|
|
|
|
|
ICU MEDICAL, INC. AND
SUBSIDIARIES |
Reconciliation of GAAP to Non-GAAP
Financial Measures (Unaudited) (Continued) |
(In thousands, except per share data) |
|
|
Adjusted EBITDA |
|
Three months endedMarch
31, |
|
2017 |
|
2016 |
GAAP net income |
$ |
55,863 |
|
|
$ |
18,160 |
|
|
|
|
|
Non-GAAP
adjustments: |
|
|
|
Interest,
net |
409 |
|
|
— |
|
Stock
compensation expense |
4,006 |
|
|
3,808 |
|
Depreciation and amortization expense |
11,594 |
|
|
4,801 |
|
Restructuring and strategic transaction |
29,401 |
|
|
— |
|
Adjustment to reverse the cost recognition related to the purchase
accounting write-up of inventory to fair market value |
22,053 |
|
|
— |
|
Bargain
purchase gain |
(63,237 |
) |
|
— |
|
Provision
for income taxes |
(10,015 |
) |
|
5,932 |
|
Total
non-GAAP adjustments |
(5,789 |
) |
|
14,541 |
|
|
|
|
|
Adjusted
EBITDA |
$ |
50,074 |
|
|
$ |
32,701 |
|
|
|
|
|
|
Adjusted diluted earnings per
share |
|
Three months endedMarch
31, |
|
2017 |
|
2016 |
GAAP diluted earnings
per share |
$ |
2.86 |
|
|
$ |
1.08 |
|
|
|
|
|
Non-GAAP
adjustments: |
|
|
|
Interest,
net |
0.02 |
|
|
— |
|
Stock
compensation expense |
0.20 |
|
|
0.23 |
|
Amortization expense |
0.17 |
|
|
0.04 |
|
Restructuring and strategic transaction |
1.50 |
|
|
— |
|
Adjustment to reverse the cost recognition related to the purchase
accounting write-up of inventory to fair market value |
1.13 |
|
|
— |
|
Bargain
purchase gain |
(3.23 |
) |
|
— |
|
Estimated
income tax impact from adjustments |
(0.97 |
) |
|
(0.09 |
) |
Adjusted
diluted earnings per share |
$ |
1.68 |
|
|
$ |
1.26 |
|
|
|
|
|
|
|
|
|
CONTACT:
ICU Medical, Inc.
Scott Lamb, Chief Financial Officer
(949) 366-2183
ICR, Inc.
John Mills, Partner
(646) 277-1254
ICU Medical (NASDAQ:ICUI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICU Medical (NASDAQ:ICUI)
Historical Stock Chart
From Apr 2023 to Apr 2024